Please login to the form below

Not currently logged in
Email:
Password:

TEVA-48125

This page shows the latest TEVA-48125 news and features for those working in and with pharma, biotech and healthcare.

Teva says chronic migraine drug is ready for phase III

Teva says chronic migraine drug is ready for phase III

Teva says chronic migraine drug is ready for phase III. TEV-48125 efficacy “ has not previously been achieved”. ... Teva's novel migraine drug TEV-48125 should start phase III trials shortly, after showing 'unprecedented' activity in a mid-stage study

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics